The results of a new muon experiment are stirring up particle physics.
The results of a Fermilab experiment might open up the standard model of particle physics.
Researchers in Singapore have found a way of controlling a Venus flytrap using electric signals from a smartphone, an innovation they hope will have a range of uses from robotics to employing the plants as environmental sensors.
Luo Yifei, a researcher at Singapore’s Nanyang Technological University (NTU), showed in a demonstration how a signal from a smartphone app sent to tiny electrodes attached to the plant could make its trap close as it does when catching a fly.
“Plants are like humans, they generate electric signals, like the ECG (electrocardiogram) from our hearts,” said Luo, who works at NTU’s School of Materials Science and Engineering.
A COVID-19 vaccine that could provide protection against existing and future strains of the COVID-19 coronavirus, and other coronaviruses, and costs about $1 a dose has shown promising results in early animal testing.
Vaccines created by UVA Health’s Steven L. Zeichner, MD, PhD, and Virginia Tech’s Xiang-Jin Meng, MD, PhD, prevented pigs from being becoming ill with a pig model coronavirus, porcine epidemic diarrhea virus (PEDV). The vaccine was developed using an innovative approach that Zeichner says might one day open the door to a universal vaccine for coronaviruses, including coronaviruses that previously threatened pandemics or perhaps even coronaviruses that cause some cases of the common cold.
Their coronavirus vaccine offers several advantages that could overcome major obstacles to global vaccination efforts. It would be easy to store and transport, even in remote areas of the world, and could be produced in mass quantities using existing vaccine-manufacturing factories.
A clinical-stage leader in immune-stimulatory vaccines for cancer announced the publication of its favorable long-term Overall Survival (OS) data from a Phase I trial evaluating a universal cancer vaccine candidate, UV1, in combination with checkpoint inhibitor ipilimumab, in patients with metastatic malignant melanoma.
UV1 is a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase.
Published in the Frontiers in Immunology journal on May 11, 2021, Norway-based Ultimovacs ASA’s UV1 vaccine candidate achieved the primary endpoints of safety and tolerability.
Influenza, commonly known as the flu virus, places a substantial burden on public health in the United States. The U.S. Centers for Disease Control and Prevention (CDC) estimates that influenza has resulted in about 9 million to 45 million diseases, 140000 to 810000 hospitalizations, and 12000 to 61000 deaths each year over the past decade.
Though flu vaccines are readily available to the public, they need to be remodeled and administered every year to combat new viral variants, which can undermine vaccine efficacy. Because of this, scientists have aimed to develop a universal vaccine that can protect against all influenza strains, and that can last for many years.
Now, researchers at the National Institute of Allergy and Infectious Diseases (NIAID)’s Vaccine Research Center (VRC) and the University of Washington School of Medicine’s Institute for Protein Design (IPD) developed a universal flu vaccine candidate using small particles (nanoparticles), which can induce a long-lasting immune response.
Despite years of hype, virtual reality headsets have yet to topple TV or computer screens as the go-to devices for video viewing.
One reason: VR can make users feel sick. Nausea and eye strain can result because VR creates an illusion of 3D viewing although the user is in fact staring at a fixed-distance 2D display. The solution for better 3D visualization could lie in a 60-year-old technology remade for the digital world: holograms.
Continue reading “MIT artificial intelligence tech can generate 3D holograms in real-time” »
The Interior Department (DOI) granted the Vineyard Wind project permission to install up to 84 turbines off the coast of Massachusetts. Once completed, the project will be able to generate up to 800 megawatts (MW), enough electricity for 400000 homes.
It won’t be the last.
These studies provide a clear proof of principle for a new type of gene therapy in which one copy of a mutated gene could be repaired from a partially intact second copy of the gene,” said Bier, senior author of the Nature Communications study and science director for the Tata Institute for Genetics and Society-UC San Diego. “The need for such a design occurs in genetic situations with patients with inherited genetic disorders, if their parents were carriers for two different mutations in the same gene.
Researchers at the University of California San Diego have laid the groundwork for a potential new type of gene therapy using novel CRISPR-based techniques.
Working in fruit flies and human cells, research led by UC San Diego Postdoctoral Scholar Zhiqian Li in Division of Biological Sciences Professor Ethan Bier’s laboratory demonstrates that new DNA repair mechanisms could be designed to address the effects of debilitating diseases and damaged cell conditions.
As researchers learn more about the brain, it has become clear that responsive neurostimulation is becoming increasingly effective at probing neural circuit function and treating neuropsychiatric disorders, such as epilepsy and Parkinson’s disease. But current approaches to designing a fully implantable and biocompatible device able to make such interventions have major limitations: their resolution isn’t high enough and most require large, bulky components that make implantation difficult with risk of complications.
A Columbia Engineering team led by Dion Khodagholy, assistant professor of electrical engineering, has come up with a new approach that shows great promise to improve such devices. Building on their earlier work to develop smaller, more efficient conformable bioelectronic transistors and materials, the researchers orchestrated their devices to create high performance implantable circuits that enable allow reading and manipulation of brain circuits. Their multiplex-then-amplify (MTA) system requires only one amplifier per multiplexer, in contrast to current approaches that need an equal number of amplifiers as number of channels.
“It is critical to be able to detect and intervene to treat brain-disorder-related symptoms, such as epileptic seizures, in real time,” said Khodagholy, a leader in bio-and neuroelectronics design. “Not only is our system much smaller and more flexible than current devices, but it also enables simultaneous stimulation of arbitrary waveforms on multiple independent channels, so it is much more versatile.
First discovered in 1984, retrons are floating ribbons of DNA in some bacteria cells that can be converted into a specific type of DNA—a single chain of DNA bases dubbed ssDNAs (yup, it’s weird). But that’s fantastic news for gene editing, because our cells’ double-stranded DNA sequences become impressionable single chains when they divide. Perfect timing for a retron bait-and-switch.
Normally, our DNA exists in double helices that are tightly wrapped into 23 bundles, called chromosomes. Each chromosome bundle comes in two copies, and when a cell divides, the copies separate to duplicate themselves. During this time, the two copies sometimes swap genes in a process called recombination. This is when retrons can sneak in, inserting their ssDNA progeny into the dividing cell instead. If they carry new tricks—say, allowing a bacteria cell to become resistant against drugs—and successfully insert themselves, then the cell’s progeny will inherit that trait.
Because of the cell’s natural machinery, retrons can infiltrate a genome without cutting it. And they can do it in millions of dividing cells at the same time.
